Drug Type Autologous CAR-T |
Synonyms CD7-Specific CAR-T Cells(Hebei Senlangbio), DVHH NS7CAR-T(Hebei Senlangbio), KO7CAR + [8] |
Target |
Action inhibitors |
Mechanism CD7 inhibitors(T-cell antigen CD7 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
T-cell Acute Lymphoblastic Leukemia/Lymphoma | Phase 1 | China | 04 Sep 2023 | |
T-Cell Lymphoma | Phase 1 | China | 01 May 2022 | |
CD7 Positive T-Cell Leukemia | Phase 1 | China | 01 Oct 2020 | |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Phase 1 | China | 01 Oct 2020 | |
Refractory T Acute Lymphoblastic Leukemia | Phase 1 | China | 01 Oct 2020 | |
Adult Lymphoblastic Lymphoma | Clinical | China | 10 May 2021 | |
CD7 Positive Acute Myeloid Leukemia | Clinical | China | 10 May 2021 | |
Mixed phenotype acute leukemia | Clinical | China | 10 May 2021 | |
Non-Hodgkin Lymphoma | Preclinical | China | 12 Oct 2022 |
Phase 1/2 | 53 | vuhihexetg(uugqlgcrtb) = wjaiervwcf ocxoinphvc (wkwivhnaya ) View more | Positive | 15 Nov 2022 | |||
Phase 1 | 15 | KO7CAR T-cells+Fludarabine Phosphate+Cyclophosphamide | jyzafwogcx(xjfexdebdo) = bpshoasheh dfabagzozw (ozgktthdnl ) View more | Positive | 12 May 2022 | ||
Phase 1 | 20 | xuykdlxqlx(yzzgeomedj) = 2pts neurotoxicity vaqvwsmzzv (mxwtsvwthn ) View more | Positive | 02 May 2022 | |||
Phase 1 | Mixed phenotype acute leukemia CD7 Positive | 5 | utejtunvex(izxjhvctqy) = bzwouidrer nsxamouagz (gptflsvtxc ) View more | Positive | 05 Nov 2021 |